血液培養検査市場：地域別、範囲および予測

血液培養検査の市場規模と予測

血液培養検査市場は、2024年に約53億9,000万米ドルと評価され、2024年から2031年にかけて約8.81%のCAGRで成長し、2031年には99億7,000万米ドルに達すると予測されています。血液培養検査は、血流中の細菌、真菌、その他の微生物の存在を検出するために使用される診断手順であり、菌血症や敗血症などの全身感染を示すことがあります。血液培養は、患者が発熱、悪寒、心拍数の上昇、意識混濁などの重篤な感染症状を示した場合に行われます。血液培養検査は、血流に広がっている可能性のある感染症を診断するために極めて重要です。

血液培養検査は、重篤な感染症を管理し、治療方針を決定するために不可欠です。血液培養検査は、速やかに対処しなければ生命を脅かす敗血症などの合併症の予防に役立ちます。

世界のヘルスケア支出の増加と、医療従事者や患者の感染症に関する知識の向上が相まって、血液培養検査の需要が増加しています。

血液培養検査の世界市場力学

世界の血液培養検査市場を形成している主な市場力学

主な促進要因

血流感染症の高い発生率：

血流感染症の高い発生率：血流感染症は、世界中で罹患率と死亡率の主な原因となっています。米国では、年間60万件以上の血流感染症が発生していると推定され、多額のヘルスケアコストがかかっています。

迅速診断技術に対する需要の高まり：

適切な抗生物質治療を行うために、血流感染症をより迅速かつ正確に診断する必要性が高まっています。このため、高度な血液培養技術の開発と導入が進んでいます。

感染症の高い有病率：

敗血症、肺炎、髄膜炎などの感染症による世界の負担は増加の一途をたどっています。例えば、2017年には、敗血症は世界で4,890万人が罹患し、1,100万人が死亡したと推定されています。

老年人口の増加：

高齢者は免疫力が低下しているため、感染症にかかりやすくなっています。世界の65歳以上の人口は、2020年の7億2,700万人から2050年には15億人に増加すると予測されています。

主な課題

解釈の複雑さ：

汚染物質と臨床的に重要な病原体を区別する必要があるため、血液培養結果の解釈は困難です。この複雑さが熟練した専門家への依存度を高め、市場成長の妨げとなる可能性があります。調査によると、検査室のかなりの割合（79％）が、正確な解釈のためには病原体の特定が重要であると考えています。

時間のかかるプロセス：

従来の血液培養検査では、結果が出るまでに数日かかることが多く、診断や治療が遅れます。米国の平均的な検査所要時間は2～3日であるため、この長引く待ち時間は患者の転帰に悪影響を及ぼす可能性があります。

自動化システムの高いコスト：

自動血液培養システムの初期投資は5万米ドルから10万米ドルと高額であるため、小規模のヘルスケア施設ではこれらの技術を採用することが困難です。

汚染のリスク：

血液培養の汚染は依然として重大な問題であり、診断や治療の決定を複雑にする偽陽性の結果につながります。培養液が汚染されると、不必要な治療が行われ、ヘルスケアコストが増加する可能性があります。

主な動向：

技術の進歩：

自動血液培養システムの革新により、検査の効率と精度が向上しています。検査技術の進歩により、自動化分野は最も速いペースで成長すると予測されます。

感染症の発生率の上昇：

医療関連感染症は増加の一途をたどっており、米国では入院患者の約31人に1人が感染症に罹患しています。

ヘルスケア支出の増加：

世界のヘルスケア支出の増加は、血液培養検査を含む高度な診断ソリューションの採用を促進しています。この動向は、より効率的な検査法の開発と実施を後押ししています。

敗血症診断への注目：

米国では年間約170万人が罹患している敗血症の診断における血液培養検査の重要性が認識されつつあり、市場の需要をさらに押し上げています。

目次

第1章 世界の血液培養検査市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 血液培養検査の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 血液培養検査の世界市場：製品別

• 概要
• 器具
• 血液培養培地
• アッセイキットと試薬
• 血液培養アクセサリー

第6章 血液培養検査の世界市場：技術別

• 概要
• ポリメラーゼ連鎖反応（PCR）
• マイクロアレイ
• 培養ベース技術
• プロテオミクス技術

第7章 血液培養検査の世界市場：用途別

• 概要
• 菌血症
• 真菌症
• マイコバクテリア検出

第8章 血液培養検査の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の血液培養検査市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Biomerieux SA
• Nanosphere, Inc.
• Becton, Dickinson and Company
• Roche Diagnostics
• Thermo Fisher Scientific, Inc.
• Bruker Corporation
• Cepheid（Danaher Corporation）

第11章 付録

• 関連調査

Blood Culture Tests Market Size And Forecast

The Blood Culture Tests Market was valued at approximately USD 5.39 Billion in 2024 and is anticipated to reach USD 9.97 Billion by 2031, growing at a CAGR of about 8.81% from 2024 to 2031. A blood culture test is a diagnostic procedure used to detect the presence of bacteria, fungi, or other microorganisms in the bloodstream, which can indicate a systemic infection such as bacteremia or sepsis. Blood cultures are ordered when patients exhibit symptoms of severe infection, such as fever, chills, rapid heart rate, or confusion. They are crucial for diagnosing infections that may have spread to the bloodstream.

Blood culture tests are vital for managing serious infections and guiding treatment decisions. They help prevent complications such as sepsis, which can be life-threatening if not addressed promptly.

Growing worldwide healthcare expenditure, combined with improved knowledge of infectious diseases among healthcare providers and patients, has increased demand for blood culture testing.

Global Blood Culture Tests Market Dynamics

The key market dynamics that are shaping the global blood culture tests market include:

Key Drivers

High Incidence of Bloodstream Infections:

Bloodstream infections are a major cause of morbidity and mortality worldwide. In the United States, it is estimated that there are over 600,000 cases of bloodstream infections annually, resulting in significant healthcare costs.

Growing Demand for Rapid Diagnostic Techniques:

There is an increasing need for faster and more accurate diagnosis of bloodstream infections to guide appropriate antibiotic therapy. This has driven the development and adoption of advanced blood culture technologies.

High Prevalence of Infectious Diseases:

The global burden of infectious diseases, such as sepsis, pneumonia, and meningitis, has been rising. For example, in 2017, sepsis was estimated to affect 48.9 million people and result in 11 million deaths worldwide.

Rising Geriatric Population:

The elderly population is more susceptible to infections due to weakened immune systems. The global population aged 65 and above is projected to increase from 727 million in 2020 to 1.5 billion in 2050.

Key Challenges:

Complexity in Interpretation:

Interpreting blood culture results can be challenging due to the need to distinguish between contaminants and clinically significant pathogens. This complexity increases reliance on skilled professionals, which can hinder market growth. Studies indicate that a significant percentage of laboratories (79%) find organism identity crucial for accurate interpretation .

Time-Consuming Process:

Traditional blood culture tests often take several days to yield results, delaying diagnosis and treatment. This prolonged wait can negatively impact patient outcomes, as the average turnaround time in the U.S. is typically 2-3 days .

High Costs of Automated Systems:

The initial investment for automated blood culture systems can be substantial, ranging from $50,000 to $100,000, making it difficult for smaller healthcare facilities to adopt these technologies .

Contamination Risks:

Blood culture contamination remains a significant issue, leading to false-positive results that complicate diagnosis and treatment decisions. Contaminated cultures can result in unnecessary treatments and increased healthcare costs.

Key Trends:

Technological Advancements:

Innovations in automated blood culture systems are improving the efficiency and accuracy of tests. The automated segment is anticipated to grow at the fastest pace, driven by advancements in testing technology.

Rising Incidence of Infections:

The prevalence of healthcare-associated infections continues to rise, with approximately 1 in 31 hospitalized patients in the U.S. suffering from such infections, driving the demand for blood culture tests.

Increased Healthcare Expenditure:

Rising global healthcare expenditure is facilitating the adoption of advanced diagnostic solutions, including blood culture tests. This trend supports the development and implementation of more efficient testing methods.

Focus on Sepsis Diagnostics:

There is a growing recognition of the importance of blood culture tests in diagnosing sepsis, which affects approximately 1.7 million individuals annually in the U.S., further propelling market demand.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Culture Systems Market Regional Analysis

Here is a more detailed regional analysis of the global blood culture systems market:

North America:

North America accounted for 35% of the global blood culture tests market revenue in 2023, making it the largest market globally. This dominance is attributed to a well-established healthcare infrastructure and advanced diagnostic capabilities.

The region experiences a significant burden of bloodstream infections, with approximately 250,000 cases occurring annually in the U.S. alone. This high incidence drives demand for effective diagnostic tools like blood culture tests.

Technological Advancements: North America is at the forefront of technological innovations in blood culture testing, including automated systems that reduce turnaround times and improve accuracy. The presence of major players such as Becton, Dickinson and Company and bioMerieux enhances market growth through continuous product development.

Government-funded programs and initiatives aimed at improving infection control and management contribute to market growth. For example, funding from agencies like BARDA supports the development of advanced diagnostic technologies, which are crucial for timely infection diagnosis.

Asia Pacific

The Asia Pacific region is expected to exhibit the highest compound annual growth rate (CAGR) of 8.32% from 2023 to 2033, reflecting a significant demand for blood culture tests driven by increasing infection rates and healthcare advancements.

The region faces a growing incidence of bloodstream infections, including sepsis and hospital-associated infections. For instance, the World Health Organization estimates that around 49 million people suffer from sepsis globally each year, with a substantial number of cases occurring in Asia Pacific.

Countries like China and India are investing heavily in healthcare infrastructure and diagnostics, which enhances the capacity for early diagnosis and treatment of infectious diseases. This investment is crucial as the region aims to improve healthcare outcomes .

Increased awareness among healthcare professionals about the importance of accurate diagnosis of bloodstream infections is leading to greater acceptance and utilization of blood culture tests in clinical settings.

Global Blood Culture Systems Market: Segmentation Analysis

The Global Blood Culture Systems Market is Segmented on the Basis of Method, Product, Technology, Application, End-User And Geography.

Blood Culture Tests Market, By Method

• Conventional/Manual Methods
• Automated Methods

Based on Method, the market is segmented into Conventional/Manual Methods and Automated Methods. The conventional/manual methods dominate over automated methods. In 2023, conventional/manual blood culture methods held approximately 64.78% of the market share, making them the most widely used technique for blood culture testing. This dominance is attributed to their long-standing familiarity and acceptance among laboratory operators.

Blood Culture Tests Market, By Product

• Consumables
• Instruments
• Software & Services

Based on Product, the market is segmented into Consumables, Instruments and Software & Services. The consumables segment accounted for the largest share of the blood culture tests market in 2023, with a revenue of approximately USD 3.5 Billion. This segment includes essential items such as blood culture media, reagents, assay kits, and other supplies necessary for conducting blood culture tests.

Blood Culture Tests Market, By Technology

• Culture-based Technology
• Molecular Technologies
• Proteomics Technology

Based on Technology, the market is segmented into Culture-based Technology, Molecular Technologies and Proteomics Technology. The culture-based technology segment accounted for the largest share of the blood culture tests market in 2023, driven by its established effectiveness in detecting bacteria and fungi in blood samples. This segment remains the gold standard for diagnosing bloodstream infections.

Blood Culture Tests Market, By Application

• Bacteremia
• Fungemia
• Mycobacterial Detection

Based on Application, the market is segmented into Bacteremia, Fungemia and Mycobacterial Detection. The bacteremia segment holds the largest share of the blood culture tests market, primarily due to the high prevalence of bacterial infections in bloodstream cases. Bacteremia is a critical condition that requires prompt diagnosis and treatment, making blood culture tests essential.

Blood Culture Tests Market, By End-User

• Hospital Laboratories
• Reference Laboratories
• Academic Research Laboratories
• Other

Based on End-User, the market is segmented into Hospital Laboratories, Reference Laboratories, Academic Research Laboratories and Other. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Blood Culture Tests Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the market is classified into North America, Europe, Asia Pacific, and the Rest of the World. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Key Players

• The "Global Blood Culture Tests Market" study report will provide valuable insight with an emphasis on the global market including some of the major players of the industry are
• Thermo Fisher Scientific, Inc., T2 Biosystems, Inc., Cepheid, Inc., Roche Diagnostics, Beckman Coulter, BioMerieux SA, IRIDICA, Bruker Corporation, Nanosphere, Inc., Becton Dickinson and Company, Abbott Laboratories, Siemens Healthineers AG, Streck, Omega Diagnostics Group PLC, Qiagen N.V., BD Diagnostics, & F. Hoffmann-La Roche Ltd, among others.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

• Blood Culture Tests Recent Developments
• In February 2023, Cepheid announced the launch of its new Xpert(R) Blood Culture Identification (BCID) test, which provides rapid identification of pathogens directly from positive blood cultures. This test significantly reduces the time required to identify infectious agents, enhancing the speed of diagnosis and treatment.
• In March 2023, Roche Diagnostics launched its new cobas(R) 8800 System for blood culture testing, which enhances the detection of pathogens in blood samples. This automated system is designed to provide faster results and improve workflow efficiency in clinical laboratories.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD CULTURE TESTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD CULTURE TESTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD CULTURE TESTS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Instruments
• 5.3 Blood Culture Media
• 5.4 Assay Kits & Reagents
• 5.5 Blood Culture Accessories

6 GLOBAL BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 Polymerase Chain Reaction (PCR)
• 6.3 Microarrays
• 6.4 Culture-Based Technology
• 6.5 Proteomics Technology

7 GLOBAL BLOOD CULTURE TESTS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Bacteremia
• 7.3 Fungemia
• 7.4 Mycobacterial Detection

8 GLOBAL BLOOD CULTURE TESTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL BLOOD CULTURE TESTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Biomerieux SA
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Nanosphere, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Becton, Dickinson and Company
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Roche Diagnostics
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Thermo Fisher Scientific, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bruker Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Cepheid (Danaher Corporation)
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments

11 Appendix

• 11.1 Related Research